Hanyu Pharmaceutical (300199.SZ): HY3003 injection approved for drug clinical trials

Zhitongcaijing · 3d ago

Zhitong Finance App News, Hanyu Pharmaceutical (300199.SZ) issued an announcement. The company recently received the “Pharmaceutical Clinical Trial Approval Notice” for HY3003 injection approved and issued by the State Drug Administration. HY3003 is a novel GLP-1R/GIPR/GCGR triple receptor agonist deployed by the company. The project uses a multi-dosage parallel development strategy. The development directions include HY3003 injections (weekly formulations), HY3003 extended-release injections (monthly formulations), and HY3003 tablets (once-daily oral formulation). The HY3003 injection approved for clinical trials is administered subcutaneously once a week and is intended for adult weight management indications.